Literature DB >> 33529238

HER2-intronic miR-4728-5p facilitates HER2 expression and accelerates cell proliferation and migration by targeting EBP1 in breast cancer.

Yu Zhou1, Yuan Yuan1, Liuyi Li1, Xueliang Wang1, Yimin Quan1, Chunyu Liu1, Mengchao Yu1, Xiuting Hu1, Xiangfeng Meng1, Zhen Zhou1, Chen-Yu Zhang1, Xi Chen1, Minghui Liu1, Chen Wang1.   

Abstract

HER2 amplification greatly contributes to the tumorigenesis of multiple cancers. Intronic miR-4728-5p is transcribed along with its host gene HER2. However, little is known about the role of miR-4728-5p in cancer. This study aims to elucidate the potential role of miR-4728-5p and the underlying mechanism in breast cancer. Kaplan-Meier analysis showed that higher expression of HER2 led to worse survival outcomes in breast cancer patients. The TCGA dataset revealed that compared to normal breast tissues, HER2 and miR-4728-5p levels were significantly upregulated in breast cancer tissues with a positive correlation. In functional assays, miR-4728-5p was confirmed to promote the proliferation and migration in breast cancer cell BT474. EBP1 was identified as a direct target of miR-4728-5p via bioinformatics and luciferase reporter assays. miR-4728-5p was further demonstrated to increase HER2 expression and promote cell proliferation and migration by directly inhibiting EBP1 in breast cancer. Taken together, the HER2-intronic miR-4728-5p/EBP1/HER2 feedback loop plays an important role in promoting breast cancer cell proliferation and migration. Our study provides novel insights for targeted therapies of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33529238      PMCID: PMC7853520          DOI: 10.1371/journal.pone.0245832

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  27 in total

Review 1.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

2.  HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.

Authors:  Marilyn A Owens; Bruce C Horten; Moacyr M Da Silva
Journal:  Clin Breast Cancer       Date:  2004-04       Impact factor: 3.225

3.  Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.

Authors:  R Pinkas-Kramarski; L Soussan; H Waterman; G Levkowitz; I Alroy; L Klapper; S Lavi; R Seger; B J Ratzkin; M Sela; Y Yarden
Journal:  EMBO J       Date:  1996-05-15       Impact factor: 11.598

Review 4.  Untangling the ErbB signalling network.

Authors:  Y Yarden; M X Sliwkowski
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

5.  The ErbB3 binding protein EBP1 regulates ErbB2 protein levels and tamoxifen sensitivity in breast cancer cells.

Authors:  Yan Lu; Hua Zhou; Wantao Chen; Yuexing Zhang; Anne W Hamburger
Journal:  Breast Cancer Res Treat       Date:  2010-04-09       Impact factor: 4.872

6.  Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.

Authors:  Christopher W Gregory; Young E Whang; Wesley McCall; Xiaoyin Fei; Yuanbo Liu; Liliana A Ponguta; Frank S French; Elizabeth M Wilson; H Shelton Earp
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

Review 7.  Regulation of microRNA function in animals.

Authors:  Luca F R Gebert; Ian J MacRae
Journal:  Nat Rev Mol Cell Biol       Date:  2019-01       Impact factor: 94.444

8.  ErbB3-binding protein EBP1 decreases ErbB2 levels via a transcriptional mechanism.

Authors:  Arundhati Ghosh; Smita Awasthi; Anne W Hamburger
Journal:  Oncol Rep       Date:  2012-12-14       Impact factor: 3.906

9.  The HER2-encoded miR-4728-3p regulates ESR1 through a non-canonical internal seed interaction.

Authors:  Inga Newie; Rolf Søkilde; Helena Persson; Dorthe Grabau; Natalia Rego; Anders Kvist; Kristoffer von Stedingk; Håkan Axelson; Åke Borg; Johan Vallon-Christersson; Carlos Rovira
Journal:  PLoS One       Date:  2014-05-14       Impact factor: 3.240

10.  Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy.

Authors:  Konstantinos V Floros; Timothy L Lochmann; Bin Hu; Carles Monterrubio; Mark T Hughes; Jason D Wells; Cristina Bernadó Morales; Maninderjit S Ghotra; Carlotta Costa; Andrew J Souers; Sosipatros A Boikos; Joel D Leverson; Ming Tan; Violeta Serra; Jennifer E Koblinski; Joaquin Arribas; Aleix Prat; Laia Paré; Todd W Miller; Mikhail G Dozmorov; Hisashi Harada; Brad E Windle; Maurizio Scaltriti; Anthony C Faber
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.